AAAAAA
Results: 1-25/54
Authors:
BLAY JY
JUDSON I
RODENHUIS S
HERMANS C
SMITH M
VANGLABBEKE M
VERWEIJ J
Citation: Jy. Blay et al., A PHASE-II STUDY OF RALTITREXED (TOMUDEX) AS 2ND OR 3RD LINE TREATMENT FOR PATIENTS (PTS) WITH ADVANCED SOFT-TISSUE SARCOMAS (ASTS) REFRACTORY TO DOXORUBICIN CONTAINING REGIMENS, Annals of oncology, 9, 1998, pp. 566-566
Authors:
TRANCHAND B
PHILIP I
CLAPISSON G
PEGUY M
BERNARD E
BLAY JY
ARDIET CJ
DROZ JP
Citation: B. Tranchand et al., CYCLOPHOSPHAMIDE KINETIC-PARAMETERS AND CIRCULATING BLOOD STEM-CELL COLLECTION PRIOR TO FIRST-LINE HIGH-DOSE CHEMOTHERAPY FOR METASTATIC BREAST-CANCER, Annals of oncology, 9, 1998, pp. 482-482
Authors:
ARDIET CJ
BERNARD E
PEGUY M
BLAY JY
TRANCHAND B
DROZ JP
Citation: Cj. Ardiet et al., PLASMA PHARMACOKINETICS OF HIGH-DOSE THIOTEPA AND CYCLOPHOSPHAMIDE ADMINISTERED SIMULTANEOUSLY AS CONTINUOUS 48-HOUR INFUSION IN BREAST-CANCER PATIENTS, Annals of oncology, 9, 1998, pp. 501-501
Authors:
COUTEAU C
MERADBOUDIA Z
LOTZ JP
LINASSIER C
BLAY JY
GLIGOROV J
ANDRE T
IZRAEL V
Citation: C. Couteau et al., TANDEM HIGH-DOSE CHEMOTHERAPY COMBINING VP-16 (1,800 MG M(2)) AND IFOSFAMIDE (IFM, 18,000 MG/M(2)) SUPPORTED BY AUTOLOGOUS STEM-CELL TRANSPLANTATION FOR POOR-PROGNOSIS SOFT-TISSUE SARCOMAS (STS) - A PILOT-STUDY/, Annals of oncology, 9, 1998, pp. 696-696
Authors:
MENETRIERCAUX C
MONTMAIN G
MAGAUD JP
CAUX C
BLAY JY
Citation: C. Menetriercaux et al., INHIBITION OF DENDRITIC CELL-DIFFERENTIATION FROM PROGENITORS BY TUMOR-CELLS - PROTECTING EFFECT OF IL-4, Journal of leukocyte biology, 1998, pp. 1-1
Authors:
BLAY JY
CONROY T
CHEVREAU C
THYSS A
QUESNEL N
EGHBALI H
BOUABDALLAH R
COIFFIER B
WAGNER JP
LEMEVEL A
DRAMAISMARCEL D
BAUMELOU E
CHAUVIN F
BIRON P
Citation: Jy. Blay et al., HIGH-DOSE METHOTREXATE FOR THE TREATMENT OF PRIMARY CEREBRAL LYMPHOMAS - ANALYSIS OF SURVIVAL AND LATE NEUROLOGIC TOXICITY IN A RETROSPECTIVE SERIES, Journal of clinical oncology, 16(3), 1998, pp. 864-871
Authors:
BLAY JY
Citation: Jy. Blay, PRODUCTION OF CYTOKINES IN-VIVO IN PATIENTS WITH CANCER - RELEVANCE TO TUMOR BEHAVIOR, Pathologie et biologie, 46(2), 1998, pp. 137-137
Authors:
BLAY JY
SEBBAN C
SURBIGUET C
OUACHEE M
PHILIP I
PHILIP T
BIRON P
Citation: Jy. Blay et al., HIGH-DOSE CHEMOTHERAPY WITH HEMATOPOIETIC STEM-CELL TRANSPLANTATION IN PATIENTS WITH MANTLE CELL OR DIFFUSE CENTROCYTIC NON-HODGKINS-LYMPHOMAS - A SINGLE-CENTER EXPERIENCE ON 18 PATIENTS, Bone marrow transplantation, 21(1), 1998, pp. 51-54
Authors:
LOTZ JP
LINASSIER C
BLAY JY
Citation: Jp. Lotz et al., TANDEM HIGH-DOSE CHEMOTHERAPY (HDCT) COMBINING VP-16 (1.800 MG M-2) AND IFOSFAMIDE (IFM, 18.000 MG/M-2) SUPPORTED BY AUTOLOGOUS STEM-CELL TRANSPLANTATION (ASCT) FOR POOR-PROGNOSIS SOFT-TISSUE SARCOMAS (STS) - A PILOT-STUDY/, Bone marrow transplantation, 21, 1998, pp. 794-794
Authors:
RAYCOQUARD I
BIRON P
BACHELOT T
GUASTALLA JP
CATIMEL G
MERROUCHE Y
DROZ JP
CHAUVIN F
BLAY JY
Citation: I. Raycoquard et al., VINORELBINE AND CISPLATIN (CIVIC REGIMEN) FOR THE TREATMENT OF METASTATIC BREAST-CARCINOMA AFTER FAILURE OF ANTHRACYCLINE-CONTAINING AND ORPACLITAXEL-CONTAINING REGIMENS/, Cancer, 82(1), 1998, pp. 134-140
Authors:
BLAY JY
Citation: Jy. Blay, ADJUVANT TREATMENT FOR LOCALIZED BREAST-CANCER HAVING A HIGH RECURRENCE RISK - AND NOW ... DIPHOSPHONATES, Bulletin du cancer, 85(9), 1998, pp. 741-741
Authors:
BLAY JY
Citation: Jy. Blay, CARCINOMAS LINKED TO AIDS, Bulletin du cancer, 85(8), 1998, pp. 673-673
Authors:
VOORZANGERROUSSELOT N
FAVROT MC
BLAY JY
Citation: N. Voorzangerrousselot et al., RESISTANCE TO CYTOTOXIC CHEMOTHERAPY-INDUCED BY CD40 LIGAND IN LYMPHOMA-CELLS, Blood, 92(9), 1998, pp. 3381-3387
Authors:
BLAY JY
LACESNE A
MERMET C
MAUGARD C
RAVAUD A
CHEVREAU C
SEBBAN C
GUASTALLA JP
BIRON P
RAYCOQUARD I
Citation: Jy. Blay et al., A RISK MODEL FOR THROMBOCYTOPENIA REQUIRING PLATELET TRANSFUSION AFTER CYTOTOXIC CHEMOTHERAPY, Blood, 92(2), 1998, pp. 405-410
Authors:
BLAY JY
GOMEZ F
SEBBAN C
BACHELOT T
BIRON P
GUGLIELMI C
HAGENBEEK A
SOMERS R
CHAUVIN F
PHILIP T
Citation: Jy. Blay et al., THE INTERNATIONAL PROGNOSTIC INDEX CORRELATES TO SURVIVAL IN PATIENTSWITH AGGRESSIVE LYMPHOMA IN RELAPSE - ANALYSIS OF THE PARMA TRIAL, Blood, 92(10), 1998, pp. 3562-3568
Authors:
BOUFFET E
PHILIP T
NEGRIER C
FFRENCH M
FRAPPAZ D
GENTILHOMME O
GIANELLABORRADORI A
BRUNATMENTIGNY M
BLAY JY
Citation: E. Bouffet et al., PHASE-I STUDY OF INTERLEUKIN-6 IN CHILDREN WITH SOLID TUMORS IN RELAPSE, European journal of cancer, 33(10), 1997, pp. 1620-1626
Authors:
BASTION YB
BLAY JY
DIVINE M
BRICE P
BORDESSOULE D
SEBBAN C
BLANC M
TILLY T
LEDERLIN P
DECONINCK E
SALLES B
DUMONTET C
BRIERE J
COIFFIER B
Citation: Yb. Bastion et al., ELDERLY PATIENTS WITH AGGRESSIVE NON-HODGKINS-LYMPHOMA - DISEASE PRESENTATION, RESPONSE TO TREATMENT, AND SURVIVAL - A GROUPE DETUDE DES LYMPHOMES DE LADULTE STUDY ON 453 PATIENTS OLDER THAN 69 YEARS, Journal of clinical oncology, 15(8), 1997, pp. 2945-2953
Authors:
CHOUAIB S
ASSELINPATUREL C
MAMICHOUAIB F
CAIGNARD A
BLAY JY
Citation: S. Chouaib et al., THE HOST-TUMOR IMMUNE CONFLICT - FROM IMMUNOSUPPRESSION TO RESISTANCEAND DESTRUCTION, Immunology today, 18(10), 1997, pp. 493-497
Authors:
BLAY JY
ROSSI JF
WIJDENES J
MENETRIERCAUX C
SCHEMANN S
NEGRIER S
PHILIP T
FAVROT M
Citation: Jy. Blay et al., ROLE OF INTERLEUKIN-6 IN THE PARANEOPLASTIC INFLAMMATORY SYNDROME-ASSOCIATED WITH RENAL-CELL CARCINOMA, International journal of cancer, 72(3), 1997, pp. 424-430
Authors:
BLAY JY
Citation: Jy. Blay, PRIMARY NON-HODGKINS-LYMPHOMA OF THE BRAI N IN NON IMMUNOSUPPRESSED PATIENTS, Bulletin du cancer, 84(10), 1997, pp. 976-980
Authors:
BAIN C
MERROUCHE Y
PUISIEUX I
BLAY JY
NEGRIER S
BONADONA V
LASSET C
LANIER F
DUC A
GEBUHRER L
PHILIP T
FAVROT MC
Citation: C. Bain et al., CORRELATION BETWEEN CLINICAL-RESPONSE TO INTERLEUKIN-2 AND HLA PHENOTYPES IN PATIENTS WITH METASTATIC RENAL-CELL CARCINOMA, British Journal of Cancer, 75(2), 1997, pp. 283-286
Authors:
VOORZANGERROUSSELOT N
BLAY JY
Citation: N. Voorzangerrousselot et Jy. Blay, RESISTANCE TO CYTOTOXIC DRUG-INDUCED APOPTOSIS TRIGGERED BY CD40 LIGAND IN LYMPHOMA-CELLS, Blood, 90(10), 1997, pp. 324-324
Authors:
SEBBAN C
BLAY JY
SURBIGUET C
FALCHERO L
PHILIP I
PHILIP T
BIRON P
Citation: C. Sebban et al., DHAP REGIMEN - A SAFE AND EFFECTIVE CHEMOTHERAPY FOR DIFFUSE CENTROCYTIC LYMPHOMA (DCL) AND MANTLE CELL LYMPHOMA (MCL) - A STUDY OF 23 CASES, Blood, 90(10), 1997, pp. 844-844
Authors:
BONNOTTE B
BURDILES AM
CHEHIMI J
CARAYOL G
PARDOUX C
DIETRICH PY
KUBIN M
BLAY JY
CAIGNARD A
IBRAHIM A
ROBINET E
HAYAT M
PICO JL
BOURHIS JH
CHOUAIB S
Citation: B. Bonnotte et al., SERUM INTERLEUKIN-12 LEVELS IN PATIENTS UNDERGOING ALLOGENEIC OR AUTOLOGOUS BONE-MARROW TRANSPLANTATION, European cytokine network, 7(3), 1996, pp. 389-394
Authors:
TARTOUR E
BLAY JY
DORVAL T
ESCUDIER B
MOSSERI V
DOUILLARD JY
DENEUX L
GORIN I
NEGRIER S
MATHIOT C
POUILLART P
FRIDMAN WH
Citation: E. Tartour et al., PREDICTORS OF CLINICAL-RESPONSE TO INTERLEUKIN-2-BASED IMMUNOTHERAPY IN MELANOMA PATIENTS - A FRENCH MULTIINSTITUTIONAL STUDY, Journal of clinical oncology, 14(5), 1996, pp. 1697-1703